Zacks Research Has Positive Estimate for Avantor Q2 Earnings

Avantor, Inc. (NYSE:AVTR - Free Report) - Analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for shares of Avantor in a research note issued on Tuesday, December 10th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Avantor's current full-year earnings is $0.98 per share.

A number of other research firms also recently weighed in on AVTR. Wells Fargo & Company decreased their price objective on Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Monday, October 28th. UBS Group cut their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, October 8th. Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $27.69.

Avantor Price Performance

Avantor stock traded down $0.29 during midday trading on Friday, reaching $22.24. The company's stock had a trading volume of 1,754,300 shares, compared to its average volume of 6,464,873. The stock has a market cap of $15.14 billion, a PE ratio of 48.98, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor has a 52 week low of $19.59 and a 52 week high of $28.00. The business has a 50-day moving average price of $22.53 and a 200-day moving average price of $23.54.

Hedge Funds Weigh In On Avantor

Several large investors have recently added to or reduced their stakes in AVTR. Blue Trust Inc. boosted its holdings in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock worth $31,000 after acquiring an additional 1,391 shares during the last quarter. UMB Bank n.a. bought a new position in shares of Avantor during the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC grew its holdings in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after acquiring an additional 835 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock worth $70,000 after acquiring an additional 1,285 shares during the period. Finally, ORG Partners LLC grew its stake in Avantor by 5,773.0% in the 2nd quarter. ORG Partners LLC now owns 5,873 shares of the company's stock valued at $122,000 after purchasing an additional 5,773 shares during the period. Institutional investors own 95.08% of the company's stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.